Oncology and Cancer

Oncology means an area of medical science which deals with tumours and cancers. The word onco means mass, bulk, or tumor while logy means study. A medical practitioner who treats oncology is known as an oncologist. Usually, an oncologist deals with care and treatment once a person is diagnosed with cancer.

Cancer is an abnormal cell growth with the possibility to spread or invade to other parts of the body as well. Not all tumors are cancerous which benign tumors do not extend to other body parts. Cancer also called as a malignant neoplasm or malignant tumor.Conference Series organizes numerous Cancer conferences on different types of cancers such as breast cancer, leukemia, oral cancer, skin cancer, lung cancer, colon cancer, rectal cancer, prostate cancer, cervical cancer, melanoma and carcinoma.

Symptoms may vary depending on the type. Cancer treatment may include chemotherapy, radiation, and/or surgery. Now a day’s vaccines were also available for specific cancer.Numerous Oncology & Cancer Conferences are organized by Conference Series. 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business through different parts of the globe such as USA, Canada, Europe, UK, Middle East, UAE and other Asia Pacific region. Young Researcher Forum, Best poster awards, E-poster, Live Streaming, B2B meetings, exhibition and sponsorship opportunities are other significant features of these Cancer Meetings.

Oncology conferences and Cancer meetings provide an excellent opportunity for the budding scientists and young researchers through its special initiatives like Young Researcher Forum, Poster Presentation and E-poster and Live Streaming, B2B and Scientific Meetings. B2B Meetings are a quick and easy way to meet potential cooperation partners.About 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008 worldwide, with 56% of the cases and 64% of the deaths in the economically developing world. Breast cancer, the most common tumour in women, presents a high survival percentage: 83% of patients have survived this type of cancer after five years. Lung cancer is one of the most aggressive tumors and survival after five years is very low: only 10% of patients diagnosed with a malignant neoplasm survive for more than five years.

Colorectal cancer (of the colon and rectum), the most common malignant tumour if we group men and women together, presents an average survival rate of 50-55% five years after diagnosis, meaning that half the patients survive this form of cancer. Prostate cancer, today the most common tumour in men, has an increasingly favourable prognosis, with a global survival rate of 76%, which is higher in young adults. Ovarian cancer presents a very varied prognosis depending on age: whilst 70% of the group between 15 and 44 years survives this form of cancer, this is the case for only 19% of those over 74 years-old.The global cancer/tumor profiling market was valued at $13.30 billion in 2012. At the end of 2013, the market is estimated to be $14.99 billion and is poised to reach around $35 billion by 2018, growing at a CAGR of 18.50% from 2013 to 2018.

Global oncology spending hit $91 billion for 2013 and it's growing at a 5% clip annually, which will cross $100 billion in 2015. The key players in the cancer/tumor profiling market are Boreal Genomics Inc. (U.S.), Caris Life Sciences (U.S.), Genomic Health Inc. (U.S.), Illumina Inc. (U.S.), Life Technologies Corporation (U.S.), NeoGenomics Laboratories (U.S.), Oxford Gene Technology Ltd. (U.K.), Precision Therapeutics Inc. (U.S.), bioTheranostics (U.S.), Proteome Sciences PLC (U.K.), Agendia (The Netherlands), Nanostring Technologies (U.S.), Rational Therapeutics (U.S.), Oncopath Laboratories (U.S.), and RiboMed BiotechnologiesInc. (U.S.). Global cancer diagnostics market is expected to reach $13.1 Billion in 2020 from an estimated $7.1 Billion in 2015, growing at a CAGR of 12.9%. The market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW).

The cancer diagnostics market in Asia is expected to grow at the highest rate from 2015 to 2020. According to the market the global oncology drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of cancer biosimilars market by 2020.Conference Series LLC has designed global platforms to interact and collaborate with renowned speakers, experts and industry professionals at its 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on diverse Medical, Pharma, Engineering, Science, Technology and Business field. Oncology and Cancer conferences organized by Conference Series LLC focuses on all types of common and rare cancers, as well as various diagnosis and treatment modalities.

Cancer is the name given to a collection of related diseases, class of diseases characterized by out-of-control cell growth. In all types of cancer, some of the body’s cells begin to divide without stopping and spread into surrounding tissues. Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Cancer sometimes begins in one part of the body before spreading to other areas. This process is known as metastasis. Causes and presentation are the other major aspects of cancer research, there are few common causes whereas unique and organ specific cancer causes were also found. Research is prominent and promising in the area of organ specific research for better understanding of organ specific cancer and implementing personalized therapeutics options.

The study of cancer and tumors are known as Oncology. The term oncology can be segregated literally into two parts "onco" means bulk, mass, or tumor while "-logy" means study. A doctor who specializes in treating people with cancer is called an oncologist. Usually, an oncologist manages care and treatment once a person is diagnosed with cancer. Scope and importance. Cancer is considered to be one of the leading causes of morbidity and mortality worldwide. It is a complex health problem that requires a multidisciplinary approach. This approach is far reaching and ranges from health promotion to prevention and screening, diagnosis, treatment, rehabilitation and palliative caret’s crucial to remember that cancer is not one disease – it’s more than 200, all different, unique diseases, which require different approaches for treatment. Treatments that work for some cancers don’t work for others and sometimes those treatments simply stop working.

Cancer research can span from cancer prevention to laboratory research, from clinical trials to quality-of-life research for survivors.About 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008 worldwide, with 56% of the cases and 64% of the deaths in the economically developing world. Breast cancer, the most common tumour in women, presents a high survival percentage: 83% of patients have survived this type of cancer after five years. Lung cancer is one of the most aggressive tumors and survival after five years is very low: only 10% of patients diagnosed with a malignant neoplasm survive for more than five years.

According to the American Cancer Society, Cancer is the second most common cause of death in the US and accounts for nearly 1 of every 4 deaths. The World Health Organization estimates that, worldwide, there were 4 million new cancer cases and 8.2 million cancer-related deaths in 2012. The financial costs of cancer in the US per year are an estimated $263.8 billion in medical costs and lost productivity. According to the World Health Organization (WHO), the numbers of new cancer cases is expected to rise by about 70% over the next 20 years.